{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:00:10Z","timestamp":1790370010591,"version":"4.1.0"},"reference-count":231,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,9]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Chemotherapy-induced nausea and vomiting (CINV) remains one of the most quality of life limiting toxicities of cancer therapy. Decades of trials have produced robust antiemetic evidence, but their applicability to resource-limited settings where guideline-recommended regimens are frequently inaccessible has not been characterized.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We reviewed the reference lists of the 2023 MASCC\/ESMO, 2025 NCCN, and 2020 ASCO antiemetic guidelines to identify all primary research articles cited as evidence for antiemetic therapy. Review articles were excluded. For each study, we extracted country of origin, income classification, age, sex distribution, primary cancer type, chemotherapy regimen, chemotherapy emetogenicity, and antiemetic regimen. Findings were synthesized descriptively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n From the reference list, 213 articles were identified. Two could not be retrieved and one was identified as a review, leaving 210 studies for extraction. When the same patient population was reported across multiple studies, the reports were consolidated and represented by the most comprehensive study, resulting in 195 unique populations for analysis. Most studies enrolled patients receiving highly emetogenic chemotherapy (63.1%), followed by moderately emetogenic (27.2%), minimally emetogenic (8.7%), and low emetogenic (1.0%) regimens. The evidence base was overwhelmingly derived from high-income countries (HICs): Of 191 studies with a determinate income classification, 82.7% originated in HICs and only 17.3% in low- and middle-income countries, persisting across every emetogenicity category.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The evidence supporting contemporary CINV guidelines is concentrated in high-income settings. As alternative, lower-cost antiemetic regimens for resource-limited settings are derived from this same evidence base, further studies are needed to assess their effectiveness in these settings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00520-026-11103-0","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T01:35:29Z","timestamp":1786757729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global inequitable distribution of seminal studies of chemotherapy-induced nausea and vomiting"],"prefix":"10.1007","volume":"34","author":[{"given":"Gregory W.","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigeng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"11103_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd012775.pub2","author":"V Piechotta","year":"2021","unstructured":"Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I et al (2021) Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta\u2010analysis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd012775.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"11103_CR2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R (2016) Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol 99:13\u201336","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"11103_CR3","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356\u20131367","journal-title":"N Engl J Med"},{"issue":"8","key":"11103_CR4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-018-4237-7","volume":"26","author":"R Chow","year":"2018","unstructured":"Chow R, Warr DG, Navari RM, Tsao M, Popovic M, Chiu L et al (2018) Should palonosetron be a preferred 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer 26(8):2519\u20132549","journal-title":"Support Care Cancer"},{"issue":"2","key":"11103_CR5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.21037\/apm.2018.03.09","volume":"7","author":"R Chow","year":"2018","unstructured":"Chow R, Tsao M, Chiu L, Popovic M, Milakovic M, Lam H et al (2018) Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Annals of Palliative Medicine 7(2):221\u2013233","journal-title":"Annals of Palliative Medicine"},{"issue":"11","key":"11103_CR6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s00520-024-08934-0","volume":"32","author":"R Chow","year":"2024","unstructured":"Chow R, Celio L, Im J, Caini S, Eng L, Prsic E et al (2024) Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Support Care Cancer 32(11):736","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR7","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E et al (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29(7):3439\u20133459","journal-title":"Support Care Cancer"},{"issue":"1","key":"11103_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00520-023-08219-y","volume":"32","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Jordan K, Scott\u00e9 F (2023) MASCC\/ESMO antiemetic guidelines: introduction to the 2023 guidelines update. Support Care Cancer 32(1):57","journal-title":"Support Care Cancer"},{"key":"11103_CR9","unstructured":"National Comprehensive Cancer Network (2025) NCCN Clinical practice guidelines in oncology (NCCN Guidelines\u00ae): antiemesis. National Comprehensive Cancer Network.\u00a0https:\/\/www.nccn.org\/guidelines\/nccn-guidelines"},{"issue":"24","key":"11103_CR10","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782\u20132797","journal-title":"J Clin Oncol"},{"issue":"3","key":"11103_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00520-025-09211-4","volume":"33","author":"SM Bosnjak","year":"2025","unstructured":"Bosnjak SM, Zilic A, Radhakrishnan V, Ostwal V, Aapro M, Iihara H et al (2025) MASCC antiemetic consensus recommendations: resource-limited settings. Support Care Cancer 33(3):181","journal-title":"Support Care Cancer"},{"issue":"6","key":"11103_CR12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070399","volume":"13","author":"S Orangi","year":"2023","unstructured":"Orangi S, Orangi T, Kabubei KM, Honda A (2023) Understanding factors influencing the use of clinical guidelines in low-income and middle-income settings: a scoping review. BMJ Open 13(6):e070399","journal-title":"BMJ Open"},{"key":"11103_CR13","doi-asserted-by":"crossref","unstructured":"participants of the MECC, Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2).\u00a0https:\/\/www.esmoopen.com\/article\/S2059-7029(23)01436-9\/fulltext","DOI":"10.1016\/j.esmoop.2023.102195"},{"key":"11103_CR14","doi-asserted-by":"crossref","unstructured":"(1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. Ann Oncol 6(8):805\u201310","DOI":"10.1093\/oxfordjournals.annonc.a059320"},{"key":"11103_CR15","doi-asserted-by":"crossref","unstructured":"(2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22(4):725\u20139","DOI":"10.1200\/JCO.2004.09.040"},{"issue":"5","key":"11103_CR16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","volume":"21","author":"M Aapro","year":"2010","unstructured":"Aapro M, Fabi A, Nol\u00e8 F, Medici M, Steger G, Bachmann C et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083\u20131088","journal-title":"Ann Oncol"},{"issue":"8","key":"11103_CR17","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, Pel\u00e1ez I, Rodr\u00edguez-Lescure \u00c1, Pastorelli D et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986\u20131992","journal-title":"Ann Oncol"},{"issue":"7","key":"11103_CR18","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25(7):1328\u20131333","journal-title":"Ann Oncol"},{"issue":"1","key":"11103_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF00258206","volume":"7","author":"MS Aapro","year":"1981","unstructured":"Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol 7(1):11\u201314","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"11103_CR20","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441\u20131449","journal-title":"Ann Oncol"},{"issue":"5","key":"11103_CR21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.1984.2.5.466","volume":"2","author":"MS Aapro","year":"1984","unstructured":"Aapro MS, Plezia PM, Alberts DS, Graham V, Jones SE, Surwit EA et al (1984) Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 2(5):466\u2013471","journal-title":"J Clin Oncol"},{"issue":"3","key":"11103_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jnci.2017.05.001","volume":"29","author":"R Abdel-Malek","year":"2017","unstructured":"Abdel-Malek R, Abbas N, Shohdy KS, Ismail M, Fawzy R, Salem DS et al (2017) Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy. J Egypt Natl Canc Inst 29(3):155\u2013158","journal-title":"J Egypt Natl Canc Inst"},{"issue":"2","key":"11103_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","volume":"24","author":"M Abe","year":"2016","unstructured":"Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S et al (2016) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 24(2):675\u2013682","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR24","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1007\/s00520-016-3100-y","volume":"24","author":"N Adra","year":"2016","unstructured":"Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z et al (2016) Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study. Support Care Cancer 24(7):2837\u20132842","journal-title":"Support Care Cancer"},{"issue":"32","key":"11103_CR25","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"C Albany","year":"2012","unstructured":"Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group study. J Clin Oncol 30(32):3998\u20134003","journal-title":"J Clin Oncol"},{"issue":"3","key":"11103_CR26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/mco.2015.724","volume":"4","author":"K Aridome","year":"2016","unstructured":"Aridome K, Mori SI, Baba K, Yanagi M, Hamanoue M, Miyazono F et al (2016) A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Mol Clin Oncol 4(3):393\u2013398","journal-title":"Mol Clin Oncol"},{"issue":"24","key":"11103_CR27","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1002\/cncr.24630","volume":"115","author":"W Arpornwirat","year":"2009","unstructured":"Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM (2009) Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115(24):5807\u20135816","journal-title":"Cancer"},{"key":"11103_CR28","doi-asserted-by":"crossref","unstructured":"Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivi\u00e8re A et al (1996) A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32a(5):807\u201313","DOI":"10.1016\/0959-8049(96)00025-1"},{"issue":"9","key":"11103_CR29","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1007\/s00520-019-4645-3","volume":"27","author":"G Badalamenti","year":"2019","unstructured":"Badalamenti G, Incorvaia L, Messina C, Musso E, Casarin A, Ricciardi MR et al (2019) One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. Support Care Cancer 27(9):3593\u20133597","journal-title":"Support Care Cancer"},{"issue":"27","key":"11103_CR30","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472\u20134478","journal-title":"J Clin Oncol"},{"issue":"10","key":"11103_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00520-010-0990-y","volume":"19","author":"RV Boccia","year":"2011","unstructured":"Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19(10):1609\u20131617","journal-title":"Support Care Cancer"},{"issue":"12","key":"11103_CR32","first-page":"1038","volume":"82","author":"J Bonneterre","year":"1995","unstructured":"Bonneterre J, Hecquet B (1995) Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study Bull Cancer 82(12):1038\u20131043","journal-title":"A cross-over study Bull Cancer"},{"key":"11103_CR33","volume":"10","author":"HR Bright","year":"2024","unstructured":"Bright HR, Singh A, Joel A, Georgy JT, John AO, Rajkumar P et al (2024) Randomized placebo-controlled trial of topical capsaicin for delayed chemotherapy-induced nausea and vomiting. JCO Glob Oncol 10:e2400130","journal-title":"JCO Glob Oncol"},{"issue":"8","key":"11103_CR34","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41409-018-0106-8","volume":"53","author":"J Bubalo","year":"2018","unstructured":"Bubalo J, Mulverhill K, Meyers G, Hayes-Lattin B, Maziarz R (2018) A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 53(8):1010\u20131018","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"11103_CR35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/10781552231173863","volume":"30","author":"JS Bubalo","year":"2024","unstructured":"Bubalo JS, Radke JL, Bensch KG, Chen AI, Misra S, Maziarz RT (2024) A phase II trial of netupitant\/palonosetron for prevention of chemotherapy-induced nausea\/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation. J Oncol Pharm Pract 30(2):304\u2013312","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"11103_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10637-020-00903-8","volume":"38","author":"J Cao","year":"2020","unstructured":"Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y et al (2020) Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Invest New Drugs 38(2):507\u2013514","journal-title":"Invest New Drugs"},{"issue":"3","key":"11103_CR37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1078155214524809","volume":"21","author":"F Caracuel","year":"2015","unstructured":"Caracuel F, Mu\u00f1oz N, Ba\u00f1os U, Ramirez G (2015) Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital. J Oncol Pharm Pract 21(3):163\u2013169","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"11103_CR38","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/1078155218808084","volume":"25","author":"AS Cass","year":"2019","unstructured":"Cass AS, Odinet JS, Valgus JM, Crona DJ (2019) Infusion reactions following administration of intravenous rolapitant at an academic medical center. J Oncol Pharm Pract 25(7):1776\u20131783","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"11103_CR39","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archinte.1983.00350070063012","volume":"143","author":"PA Cassileth","year":"1983","unstructured":"Cassileth PA, Lusk EJ, Torri S, DiNubile N, Gerson SL (1983) Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med 143(7):1347\u20131349","journal-title":"Arch Intern Med"},{"issue":"30","key":"11103_CR40","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2217\/fon-2022-0330","volume":"18","author":"L Celio","year":"2022","unstructured":"Celio L, Bonizzoni E, Montani E, Aapro M (2022) Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis. Future Oncol 18(30):3389\u20133397","journal-title":"Future Oncol"},{"issue":"10","key":"11103_CR41","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1002\/onco.13851","volume":"26","author":"L Celio","year":"2021","unstructured":"Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S et al (2021) Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study. Oncologist 26(10):e1854\u2013e1861","journal-title":"Oncologist"},{"issue":"1","key":"11103_CR42","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1186\/s12885-022-10018-3","volume":"22","author":"L Celio","year":"2022","unstructured":"Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S et al (2022) Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant\/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. BMC Cancer 22(1):915","journal-title":"BMC Cancer"},{"issue":"2","key":"11103_CR43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.suponc.2011.06.007","volume":"10","author":"L Celio","year":"2012","unstructured":"Celio L, Denaro A, Agustoni F, Bajetta E (2012) Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 10(2):65\u201371","journal-title":"J Support Oncol"},{"issue":"8","key":"11103_CR44","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","volume":"19","author":"L Celio","year":"2011","unstructured":"Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19(8):1217\u20131225","journal-title":"Support Care Cancer"},{"issue":"3","key":"11103_CR45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0300891619839301","volume":"105","author":"L Celio","year":"2019","unstructured":"Celio L, Saibene G, Lepori S, Festinese F, Niger M, Raspagliesi F et al (2019) Short-course olanzapine to prevent delayed emesis following carboplatin\/paclitaxel for gynecologic cancer: a randomised study. Tumori 105(3):253\u2013258","journal-title":"Tumori"},{"issue":"14","key":"11103_CR46","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1002\/cam4.3123","volume":"9","author":"J Chang","year":"2020","unstructured":"Chang J, Chen G, Wang D, Wang G, Lu S, Feng J et al (2020) Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized phase 3 study. Cancer Med 9(14):5134\u20135142","journal-title":"Cancer Med"},{"issue":"9","key":"11103_CR47","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.11320","volume":"97","author":"SP Chawla","year":"2003","unstructured":"Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME et al (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97(9):2290\u20132300","journal-title":"Cancer"},{"key":"11103_CR48","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101480","volume":"49","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Wu Z, Shi L, Shen C, Zhang J, Hu H et al (2022) Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: a randomized, open-label, phase 3 trial. EClinicalMedicine 49:101480","journal-title":"EClinicalMedicine"},{"issue":"Suppl 1","key":"11103_CR49","first-page":"S33","volume":"26","author":"B Chevallier","year":"1990","unstructured":"Chevallier B (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer 26(Suppl 1):S33-6","journal-title":"Eur J Cancer"},{"issue":"1","key":"11103_CR50","first-page":"176","volume":"68","author":"B Chevallier","year":"1993","unstructured":"Chevallier B (1993) The control of acute cisplatin-induced emesis\u2013a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group Br J Cancer 68(1):176\u2013180","journal-title":"Granisetron Study Group Br J Cancer"},{"issue":"10","key":"11103_CR51","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24(10):2065\u20132071","journal-title":"Biol Blood Marrow Transplant"},{"key":"11103_CR52","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","volume":"54","author":"M Clemons","year":"2020","unstructured":"Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A et al (2020) A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. Breast 54:278\u2013285","journal-title":"Breast"},{"issue":"3","key":"11103_CR53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jand.2023.09.003","volume":"124","author":"M Crichton","year":"2024","unstructured":"Crichton M, Marshall S, Isenring E, Lohning A, McCarthy AL, Molassiotis A et al (2024) Effect of a standardized ginger root powder regimen on chemotherapy-induced nausea and vomiting: a multicenter, double-blind, placebo-controlled randomized trial. J Acad Nutr Diet 124(3):313\u201330.e6","journal-title":"J Acad Nutr Diet"},{"issue":"Suppl 1","key":"11103_CR54","first-page":"S23","volume":"26","author":"DR Cupissol","year":"1990","unstructured":"Cupissol DR, Serrou B, Caubel M (1990) The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 26(Suppl 1):S23\u2013S27","journal-title":"Eur J Cancer"},{"issue":"11","key":"11103_CR55","doi-asserted-by":"crossref","first-page":"834","DOI":"10.7326\/0003-4819-113-11-834","volume":"113","author":"PH De Mulder","year":"1990","unstructured":"De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL et al (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113(11):834\u201340","journal-title":"Ann Intern Med"},{"issue":"3","key":"11103_CR56","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2003.08.028","volume":"40","author":"R de Wit","year":"2004","unstructured":"de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M et al (2004) The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 40(3):403\u2013410","journal-title":"Eur J Cancer"},{"issue":"11","key":"11103_CR57","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/acem.14062","volume":"27","author":"DJ Dean","year":"2020","unstructured":"Dean DJ, Sabagha N, Rose K, Weiss A, France J, Asmar T et al (2020) A pilot trial of topical capsaicin cream for treatment of cannabinoid hyperemesis syndrome. Acad Emerg Med 27(11):1166\u20131172","journal-title":"Acad Emerg Med"},{"issue":"1","key":"11103_CR58","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cam4.2628","volume":"9","author":"N Di Renzo","year":"2020","unstructured":"Di Renzo N, Melillo L, Porretto F, Dargenio M, Pavone V, Pastore D et al (2020) Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: a randomized, controlled study from the \u201cRete Ematologica Pugliese.\u201d Cancer Med 9(1):170\u2013178","journal-title":"Cancer Med"},{"issue":"2","key":"11103_CR59","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00520-021-06495-0","volume":"30","author":"N Di Renzo","year":"2022","unstructured":"Di Renzo N, Musso M, Scim\u00e8 R, Cupri A, Perrone T, De Risi C et al (2022) Efficacy and safety of netupitant\/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin\u2019s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. Support Care Cancer 30(2):1521\u20131527","journal-title":"Support Care Cancer"},{"issue":"11","key":"11103_CR60","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41409-020-0909-2","volume":"55","author":"N Di Renzo","year":"2020","unstructured":"Di Renzo N, Musso M, Scim\u00e8 R, Cupri A, Perrone T, De Risi C et al (2020) Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant 55(11):2114\u20132120","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"11103_CR61","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.31557\/APJCP.2020.21.6.1567","volume":"21","author":"M Ebrahimi","year":"2020","unstructured":"Ebrahimi M, Mehrzad V, Moghaddas A (2020) Adherence to ASCO for prophylaxis of acute chemotherapy- induced nausea and vomiting in Iran. Asian Pac J Cancer Prev 21(6):1567\u20131572","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"11103_CR62","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00520-007-0255-6","volume":"15","author":"LH Einhorn","year":"2007","unstructured":"Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr., Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15(11):1293\u20131300","journal-title":"Support Care Cancer"},{"issue":"11","key":"11103_CR63","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","volume":"98","author":"P Eisenberg","year":"2003","unstructured":"Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473\u20132482","journal-title":"Cancer"},{"issue":"2","key":"11103_CR64","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/annonc\/mdh047","volume":"15","author":"P Eisenberg","year":"2004","unstructured":"Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15(2):330\u2013337","journal-title":"Ann Oncol"},{"key":"11103_CR65","doi-asserted-by":"crossref","unstructured":"Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz-Rubio E et al (1996) Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer 32a(9):1523\u20139","DOI":"10.1016\/0959-8049(96)00132-3"},{"issue":"1","key":"11103_CR66","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s005209900090","volume":"8","author":"AA Fauser","year":"2000","unstructured":"Fauser AA, Pizzocaro G, Schueller J, Khayat D, Wilkinson P (2000) A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 8(1):49\u201354","journal-title":"Support Care Cancer"},{"issue":"12","key":"11103_CR67","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1200\/JCO.1993.11.12.2391","volume":"11","author":"SM Fox","year":"1993","unstructured":"Fox SM, Einhorn LH, Cox E, Powell N, Abdy A (1993) Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11(12):2391\u20132395","journal-title":"J Clin Oncol"},{"issue":"11","key":"11103_CR68","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s00520-015-2760-3","volume":"23","author":"N Furukawa","year":"2015","unstructured":"Furukawa N, Kanayama S, Tanase Y, Ito F (2015) Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin. Support Care Cancer 23(11):3317\u20133322","journal-title":"Support Care Cancer"},{"issue":"1","key":"11103_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12885-023-11070-3","volume":"23","author":"A Gao","year":"2023","unstructured":"Gao A, Guan S, Sun Y, Wang L, Meng F, Liu X et al (2023) Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. BMC Cancer 23(1):609","journal-title":"BMC Cancer"},{"issue":"1","key":"11103_CR70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1445-5994.2011.02637.x","volume":"43","author":"HF Gao","year":"2013","unstructured":"Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY (2013) Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J 43(1):73\u201376","journal-title":"Intern Med J"},{"issue":"7","key":"11103_CR71","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1007\/s00520-022-07067-6","volume":"30","author":"J Gao","year":"2022","unstructured":"Gao J, Zhao J, Jiang C, Chen F, Zhao L, Jiang Y et al (2022) Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Support Care Cancer 30(7):6225\u20136232","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR72","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/1097-0142(19941001)74:7<1945::AID-CNCR2820740720>3.0.CO;2-C","volume":"74","author":"V Gebbia","year":"1994","unstructured":"Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C et al (1994) Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 74(7):1945\u201352","journal-title":"Cancer"},{"issue":"4","key":"11103_CR73","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/annonc\/mdq457","volume":"22","author":"SA Giralt","year":"2011","unstructured":"Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD et al (2011) Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 22(4):939\u2013946","journal-title":"Ann Oncol"},{"issue":"7","key":"11103_CR74","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00520-011-1226-5","volume":"20","author":"G Gonullu","year":"2012","unstructured":"Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20(7):1435\u20131439","journal-title":"Support Care Cancer"},{"issue":"10","key":"11103_CR75","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","volume":"14","author":"R Gralla","year":"2003","unstructured":"Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570\u20131577","journal-title":"Ann Oncol"},{"issue":"4","key":"11103_CR76","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cncr.21222","volume":"104","author":"RJ Gralla","year":"2005","unstructured":"Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J et al (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104(4):864\u2013868","journal-title":"Cancer"},{"issue":"16","key":"11103_CR77","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM198110153051601","volume":"305","author":"RJ Gralla","year":"1981","unstructured":"Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW Jr et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305(16):905\u2013909","journal-title":"N Engl J Med"},{"issue":"8","key":"11103_CR78","first-page":"403","volume":"4","author":"T Grote","year":"2006","unstructured":"Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 4(8):403\u2013408","journal-title":"J Support Oncol"},{"issue":"11","key":"11103_CR79","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","volume":"29","author":"S Grunberg","year":"2011","unstructured":"Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2013EASE. J Clin Oncol 29(11):1495\u20131501","journal-title":"J Clin Oncol"},{"issue":"10","key":"11103_CR80","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","volume":"100","author":"SM Grunberg","year":"2004","unstructured":"Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261\u20132268","journal-title":"Cancer"},{"issue":"5","key":"11103_CR81","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00520-008-0535-9","volume":"17","author":"SM Grunberg","year":"2009","unstructured":"Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T et al (2009) Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17(5):589\u2013594","journal-title":"Support Care Cancer"},{"key":"11103_CR82","first-page":"53","volume":"3","author":"MJ Hafermann","year":"2011","unstructured":"Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd (2011) Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf 3:53\u201358","journal-title":"Drug Healthc Patient Saf"},{"issue":"8","key":"11103_CR83","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00520-014-2182-7","volume":"22","author":"S Hamada","year":"2014","unstructured":"Hamada S, Hinotsu S, Kawai K, Yamada S, Narita S, Kamba T et al (2014) Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer 22(8):2161\u20132166","journal-title":"Support Care Cancer"},{"issue":"2","key":"11103_CR84","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(2):242\u2013249","journal-title":"Lancet Oncol"},{"issue":"2","key":"11103_CR85","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"A Hata","year":"2022","unstructured":"Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K et al (2022) Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol 40(2):180\u2013188","journal-title":"J Clin Oncol"},{"issue":"23","key":"11103_CR86","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJM197906073002302","volume":"300","author":"TS Herman","year":"1979","unstructured":"Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300(23):1295\u20131297","journal-title":"N Engl J Med"},{"issue":"4","key":"11103_CR87","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-006-0158-y","volume":"15","author":"J Herrstedt","year":"2007","unstructured":"Herrstedt J, Sigsgaard TC, Nielsen HA, Handberg J, Langer SW, Ottesen S et al (2007) Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 15(4):417\u2013426","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR88","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s00520-018-4564-8","volume":"27","author":"J Herrstedt","year":"2019","unstructured":"Herrstedt J, Summers Y, Jordan K, von Pawel J, Jakobsen AH, Ewertz M et al (2019) Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. Support Care Cancer 27(7):2699\u20132705","journal-title":"Support Care Cancer"},{"issue":"8","key":"11103_CR89","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1200\/JCO.1996.14.8.2242","volume":"14","author":"P Hesketh","year":"1996","unstructured":"Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron comparative chemotherapy-induced emesis prevention group. J Clin Oncol 14(8):2242\u20132249","journal-title":"J Clin Oncol"},{"issue":"22","key":"11103_CR90","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2013the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112\u20134119","journal-title":"J Clin Oncol"},{"issue":"4","key":"11103_CR91","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00520-005-0914-4","volume":"14","author":"PJ Hesketh","year":"2006","unstructured":"Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD et al (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14(4):354\u2013360","journal-title":"Support Care Cancer"},{"issue":"4","key":"11103_CR92","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00520-017-3936-9","volume":"26","author":"PJ Hesketh","year":"2018","unstructured":"Hesketh PJ, Palmas M, Nicolas P (2018) Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic. Support Care Cancer 26(4):1151\u20131159","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR93","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I et al (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25(7):1340\u20131346","journal-title":"Ann Oncol"},{"issue":"15","key":"11103_CR94","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/cncr.30054","volume":"122","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S et al (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 122(15):2418\u20132425","journal-title":"Cancer"},{"issue":"10","key":"11103_CR95","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(05)70325-9","volume":"6","author":"JT Hickok","year":"2005","unstructured":"Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL et al (2005) 5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6(10):765\u2013772","journal-title":"Lancet Oncol"},{"issue":"3","key":"11103_CR96","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","volume":"156","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M et al (2020) Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study. Gynecol Oncol 156(3):629\u2013635","journal-title":"Gynecol Oncol"},{"issue":"2","key":"11103_CR97","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","volume":"25","author":"H Iihara","year":"2019","unstructured":"Iihara H, Shimokawa M, Hayashi T, Kawazoe H, Saeki T, Aiba K et al (2019) A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan. Oncologist 25(2):e373\u2013e380","journal-title":"Oncologist"},{"issue":"3","key":"11103_CR98","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10147-016-1081-y","volume":"22","author":"T Inoue","year":"2017","unstructured":"Inoue T, Kimura M, Uchida J, Nishino K, Kumagai T, Taniguchi J et al (2017) Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Int J Clin Oncol 22(3):600\u2013604","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"11103_CR99","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00520-017-3967-2","volume":"26","author":"T Ioroi","year":"2018","unstructured":"Ioroi T, Furukawa J, Kume M, Hirata S, Utsubo Y, Mizuta N et al (2018) Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy. Support Care Cancer 26(5):1419\u20131423","journal-title":"Support Care Cancer"},{"issue":"4","key":"11103_CR100","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","volume":"105","author":"A Isoda","year":"2017","unstructured":"Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T et al (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105(4):478\u2013484","journal-title":"Int J Hematol"},{"issue":"11","key":"11103_CR101","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1007\/s00520-020-05380-6","volume":"28","author":"S Ithimakin","year":"2020","unstructured":"Ithimakin S, Theeratrakul P, Laocharoenkiat A, Nimmannit A, Akewanlop C, Soparattanapaisarn N et al (2020) Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer 28(11):5335\u20135342","journal-title":"Support Care Cancer"},{"issue":"10","key":"11103_CR102","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","volume":"36","author":"Y Ito","year":"2018","unstructured":"Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M et al (2018) Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol 36(10):1000\u20131006","journal-title":"J Clin Oncol"},{"issue":"3","key":"11103_CR103","first-page":"112","volume":"8","author":"A James","year":"2017","unstructured":"James A, Nair MM, Abraham DS, Kovoor JS, Jose WM, Reghu R (2017) Effect of lorazepam in reducing psychological distress and anticipatory nausea and vomiting in patients undergoing chemotherapy. J Pharmacol Pharmacother 8(3):112\u2013115","journal-title":"J Pharmacol Pharmacother"},{"issue":"12","key":"11103_CR104","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/0959-8049(93)90101-K","volume":"29a","author":"IT Jantunen","year":"1993","unstructured":"Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L (1993) 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. Eur J Cancer 29a(12):1669\u20131672","journal-title":"Eur J Cancer"},{"issue":"1","key":"11103_CR105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4143\/crt.2017.577","volume":"51","author":"SY Jeon","year":"2019","unstructured":"Jeon SY, Han HS, Bae WK, Park MR, Shim H, Lee SC et al (2019) A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the Korean South West Oncology Group (KSWOG) study. Cancer Res Treat 51(1):90\u201397","journal-title":"Cancer Res Treat"},{"issue":"4","key":"11103_CR106","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4143\/crt.2015.464","volume":"48","author":"Y Jeong","year":"2016","unstructured":"Jeong Y, Han HS, Lee HD, Yang J, Jeong J, Choi MK et al (2016) A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res Treat 48(4):1429\u20131437","journal-title":"Cancer Res Treat"},{"issue":"11","key":"11103_CR107","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1007\/s00520-016-3304-1","volume":"24","author":"K Jordan","year":"2016","unstructured":"Jordan K, Gralla R, Rizzi G, Kashef K (2016) Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer 24(11):4617\u20134625","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR108","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ejca.2008.11.046","volume":"45","author":"K Jordan","year":"2009","unstructured":"Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ (2009) Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 45(7):1184\u20131187","journal-title":"Eur J Cancer"},{"issue":"3","key":"11103_CR109","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4143\/crt.2019.713","volume":"52","author":"JH Kang","year":"2020","unstructured":"Kang JH, Kwon JH, Lee YG, Park KU, An HJ, Sohn J et al (2020) Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly-emetogenic chemotherapy-induced nausea and vomiting. Cancer Res Treat 52(3):907\u2013916","journal-title":"Cancer Res Treat"},{"issue":"10","key":"11103_CR110","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s00520-015-2657-1","volume":"23","author":"M Karthaus","year":"2015","unstructured":"Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G et al (2015) Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). Support Care Cancer 23(10):2917\u20132923","journal-title":"Support Care Cancer"},{"issue":"3","key":"11103_CR111","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jpainsymman.2020.03.034","volume":"60","author":"M Karthaus","year":"2020","unstructured":"Karthaus M, Voisin D, Rizzi G, Ciuleanu T (2020) Phase 3 study of palonosetron IV infusion vs. IV bolus for chemotherapy-induced nausea and vomiting prophylaxis after highly emetogenic chemotherapy. J Pain Symptom Manage 60(3):568\u2013576","journal-title":"J Pain Symptom Manage"},{"key":"11103_CR112","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3332\/ecancer.2015.567","volume":"9","author":"P Kaushal","year":"2015","unstructured":"Kaushal P, Atri R, Soni A, Kaushal V (2015) Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. Ecancermedicalscience 9:567","journal-title":"Ecancermedicalscience"},{"issue":"12","key":"11103_CR113","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1634\/theoncologist.2015-0128","volume":"20","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Shin SW, Song EK, Lee NR, Kim JS, Ahn JS et al (2015) Ramosetron versus ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a multicenter, randomized phase III trial, KCSG PC10-21. Oncologist 20(12):1440\u20131447","journal-title":"Oncologist"},{"issue":"3","key":"11103_CR114","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00520-016-3463-0","volume":"25","author":"JE Kim","year":"2017","unstructured":"Kim JE, Jang JS, Kim JW, Sung YL, Cho CH, Lee MA et al (2017) Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer 25(3):801\u2013809","journal-title":"Support Care Cancer"},{"issue":"3","key":"11103_CR115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/cam4.373","volume":"4","author":"H Kimura","year":"2015","unstructured":"Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y et al (2015) Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Cancer Med 4(3):333\u2013341","journal-title":"Cancer Med"},{"issue":"6","key":"11103_CR116","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s10147-015-0823-6","volume":"20","author":"H Kitayama","year":"2015","unstructured":"Kitayama H, Tsuji Y, Sugiyama J, Doi A, Kondo T, Hirayama M (2015) Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study. Int J Clin Oncol 20(6):1051\u20131056","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"11103_CR117","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/cas.12675","volume":"106","author":"Y Komatsu","year":"2015","unstructured":"Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H et al (2015) Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 106(7):891\u2013895","journal-title":"Cancer Sci"},{"issue":"3","key":"11103_CR118","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00520-015-2905-4","volume":"24","author":"Y Kosaka","year":"2016","unstructured":"Kosaka Y, Tanino H, Sengoku N, Minatani N, Kikuchi M, Nishimiya H et al (2016) Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer 24(3):1405\u20131411","journal-title":"Support Care Cancer"},{"issue":"11","key":"11103_CR119","first-page":"1257","volume":"69","author":"MG Kris","year":"1985","unstructured":"Kris MG, Gralla RJ, Clark RA, Tyson LB, Fiore JJ, Kelsen DP et al (1985) Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 69(11):1257\u20131262","journal-title":"Cancer Treat Rep"},{"issue":"11","key":"11103_CR120","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/1097-0142(19871201)60:11<2816::AID-CNCR2820601137>3.0.CO;2-7","volume":"60","author":"MG Kris","year":"1987","unstructured":"Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S (1987) Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 60(11):2816\u201322","journal-title":"Cancer"},{"issue":"3","key":"11103_CR121","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","volume":"90","author":"H Kusagaya","year":"2015","unstructured":"Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S et al (2015) Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer 90(3):410\u2013416","journal-title":"Lung Cancer"},{"issue":"6","key":"11103_CR122","volume":"43","author":"Q Li","year":"2019","unstructured":"Li Q, Wu Y, Wang W, Deng S, Jiang C, Chen F et al (2019) Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting. Curr Probl Cancer 43(6):100462","journal-title":"Curr Probl Cancer"},{"key":"11103_CR123","doi-asserted-by":"crossref","first-page":"5954379","DOI":"10.1155\/2022\/5954379","volume":"2022","author":"G Liu","year":"2022","unstructured":"Liu G, Jin Y, Jiang Y, Zhao J, Jiang C, Zhang Z et al (2022) A comparison of the efficacy of 5 mg olanzapine and aprepitant in the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting. Int J Clin Pract 2022:5954379","journal-title":"Int J Clin Pract"},{"issue":"3","key":"11103_CR124","first-page":"436","volume":"24","author":"J Liu","year":"2015","unstructured":"Liu J, Tan L, Zhang H, Li H, Liu X, Yan Z et al (2015) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care (Engl) 24(3):436\u2013443","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"8","key":"11103_CR125","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.1997.15.8.2966","volume":"15","author":"WS Lofters","year":"1997","unstructured":"Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP et al (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15(8):2966\u20132973","journal-title":"J Clin Oncol"},{"issue":"8","key":"11103_CR126","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00520-010-0930-x","volume":"19","author":"F Longo","year":"2011","unstructured":"Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R et al (2011) Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 19(8):1159\u20131164","journal-title":"Support Care Cancer"},{"issue":"3","key":"11103_CR127","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.21037\/apm-20-1784","volume":"10","author":"A Maeda","year":"2021","unstructured":"Maeda A, Yoshida H, Inoue H, Ejiri M, Yamaguchi S, Kushihara H et al (2021) Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial. Ann Palliat Med 10(3):2699\u20132708","journal-title":"Ann Palliat Med"},{"issue":"8","key":"11103_CR128","first-page":"4527","volume":"35","author":"M Maehara","year":"2015","unstructured":"Maehara M, Ueda T, Miyahara D, Takahashi Y, Miyata K, Nam SO et al (2015) Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin. Anticancer Res 35(8):4527\u20134534","journal-title":"Anticancer Res"},{"issue":"2","key":"11103_CR129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00000421-199504000-00017","volume":"18","author":"IA Malik","year":"1995","unstructured":"Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA (1995) Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18(2):170\u2013175","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"11103_CR130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<941::AID-CNCR21>3.0.CO;2-2","volume":"77","author":"G Mantovani","year":"1996","unstructured":"Mantovani G, Macci\u00f2 A, Bianchi A, Curreli L, Ghiani M, Proto E et al (1996) Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 77(5):941\u2013948","journal-title":"Cancer"},{"issue":"1","key":"11103_CR131","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0959-8049(95)00519-6","volume":"32a","author":"A Martoni","year":"1996","unstructured":"Martoni A, Angelelli B, Guaraldi M, Strocchi E, Pannuti F (1996) An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer 32a(1):82\u201385","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"11103_CR132","first-page":"S28","volume":"26","author":"M Marty","year":"1990","unstructured":"Marty M (1990) A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group. Eur J Cancer 26(Suppl 1):S28-32","journal-title":"Eur J Cancer"},{"issue":"12","key":"11103_CR133","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199003223221205","volume":"322","author":"M Marty","year":"1990","unstructured":"Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N et al (1990) Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322(12):816\u2013821","journal-title":"N Engl J Med"},{"issue":"10","key":"11103_CR134","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/cam4.2979","volume":"9","author":"K Matsumoto","year":"2020","unstructured":"Matsumoto K, Takahashi M, Sato K, Osaki A, Takano T, Naito Y et al (2020) A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. Cancer Med 9(10):3319\u20133327","journal-title":"Cancer Med"},{"issue":"8","key":"11103_CR135","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.34088","volume":"128","author":"K Matsuura","year":"2022","unstructured":"Matsuura K, Tsurutani J, Inoue K, Tanabe Y, Taira T, Kubota K et al (2022) A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer 128(8):1692\u20131698","journal-title":"Cancer"},{"issue":"10","key":"11103_CR136","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/jog.12748","volume":"41","author":"M Matsuura","year":"2015","unstructured":"Matsuura M, Satohisa S, Teramoto M, Tanaka R, Iwasaki M, Nishikawa A et al (2015) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: a randomized, multicenter, phase-II trial. J Obstet Gynaecol Res 41(10):1607\u20131613","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"11103_CR137","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41416-023-02493-7","volume":"130","author":"H Minatogawa","year":"2024","unstructured":"Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M et al (2024) Dexamethasone-sparing on days 2\u20134 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). Br J Cancer 130(2):224\u2013232","journal-title":"Br J Cancer"},{"issue":"9","key":"11103_CR138","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00520-013-1835-2","volume":"21","author":"S Miura","year":"2013","unstructured":"Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H et al (2013) The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(9):2575\u201381","journal-title":"Support Care Cancer"},{"issue":"5","key":"11103_CR139","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N et al (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47(5):839\u201348.e4","journal-title":"J Pain Symptom Manage"},{"issue":"24","key":"11103_CR140","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJM198212093072402","volume":"307","author":"GR Morrow","year":"1982","unstructured":"Morrow GR, Morrell C (1982) Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307(24):1476\u20131480","journal-title":"N Engl J Med"},{"key":"11103_CR141","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay S, Dutta P, Banerjee S, Bhattacharya B, Biswas S, R MN (2021) Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Future Oncol 17(16):2041\u201356","DOI":"10.2217\/fon-2020-0834"},{"issue":"1","key":"11103_CR142","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00520-016-3386-9","volume":"25","author":"S Mukhopadhyay","year":"2017","unstructured":"Mukhopadhyay S, Kwatra G, Alice KP, Badyal D (2017) Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer 25(1):145\u2013154","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR143","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2023.100997","volume":"5","author":"LM Murphy","year":"2023","unstructured":"Murphy LM, Whelan AR, Griffin LB, Hamel MS (2023) A pilot randomized control trial of topical capsaicin as adjunctive therapy for nausea and vomiting of pregnancy. Am J Obstet Gynecol MFM 5(7):100997","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"2","key":"11103_CR144","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00520-008-0510-5","volume":"17","author":"M Musso","year":"2009","unstructured":"Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F et al (2009) Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 17(2):205\u2013209","journal-title":"Support Care Cancer"},{"issue":"2","key":"11103_CR145","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00520-016-3445-2","volume":"25","author":"M Nakagaki","year":"2017","unstructured":"Nakagaki M, Barras M, Curley C, Butler JP, Kennedy GA (2017) A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 25(2):607\u2013613","journal-title":"Support Care Cancer"},{"issue":"5","key":"11103_CR146","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","volume":"22","author":"M Nakamura","year":"2017","unstructured":"Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K et al (2017) A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01). Oncologist 22(5):592\u2013600","journal-title":"Oncologist"},{"issue":"9","key":"11103_CR147","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jjco\/hyx084","volume":"47","author":"K Nakashima","year":"2017","unstructured":"Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A et al (2017) A phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol 47(9):840\u2013843","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"11103_CR148","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.1995.13.5.1242","volume":"13","author":"R Navari","year":"1995","unstructured":"Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H et al (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 13(5):1242\u20131248","journal-title":"J Clin Oncol"},{"issue":"11","key":"11103_CR149","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","volume":"15","author":"RM Navari","year":"2007","unstructured":"Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 15(11):1285","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR150","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","volume":"13","author":"RM Navari","year":"2005","unstructured":"Navari RM, Einhorn LH, Passik SD, Loehrer PJ Sr, Johnson C, Mayer ML et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13(7):529\u2013534","journal-title":"Support Care Cancer"},{"issue":"5","key":"11103_CR151","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188\u2013195","journal-title":"J Support Oncol"},{"issue":"10","key":"11103_CR152","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1200\/JCO.1994.12.10.2204","volume":"12","author":"RM Navari","year":"1994","unstructured":"Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12(10):2204\u20132210","journal-title":"J Clin Oncol"},{"issue":"6","key":"11103_CR153","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655\u20131663","journal-title":"Support Care Cancer"},{"issue":"4","key":"11103_CR154","doi-asserted-by":"crossref","first-page":"141","DOI":"10.12788\/jcso.0245","volume":"14","author":"RM Navari","year":"2016","unstructured":"Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL (2016) Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 14(4):141\u2013147","journal-title":"J Community Support Oncol"},{"issue":"6","key":"11103_CR155","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2020.1052","volume":"6","author":"RM Navari","year":"2020","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C et al (2020) Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial. JAMA Oncol 6(6):895\u2013899","journal-title":"JAMA Oncol"},{"issue":"2","key":"11103_CR156","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134\u2013142","journal-title":"N Engl J Med"},{"issue":"5","key":"11103_CR157","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s13187-020-01689-2","volume":"36","author":"Z Nikbakht","year":"2021","unstructured":"Nikbakht Z, Rajabi M, Shahrasbi A, Roohi E, Hashemian F (2021) Evaluation of adherence to antiemetic treatment guidelines in patients with chemotherapy-induced nausea and vomiting in teaching hospitals in Tehran. J Cancer Educ 36(5):1022\u20131029","journal-title":"J Cancer Educ"},{"issue":"10","key":"11103_CR158","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y et al (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51(10):1274\u20131282","journal-title":"Eur J Cancer"},{"issue":"8","key":"11103_CR159","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0959-8049(94)90461-8","volume":"30a","author":"A Noble","year":"1994","unstructured":"Noble A, Bremer K, Goedhals L, Cupissol D, Dilly SG, The Granisetron Study Group (1994) A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 30a(8):1083\u20138","journal-title":"Eur J Cancer"},{"issue":"6","key":"11103_CR160","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00520-012-1696-0","volume":"21","author":"IN Olver","year":"2013","unstructured":"Olver IN, Grimison P, Chatfield M, Stockler MR, Toner GC, Gebski V et al (2013) Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 21(6):1561\u20131568","journal-title":"Support Care Cancer"},{"key":"11103_CR161","doi-asserted-by":"crossref","unstructured":"Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF et al (2024) Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial. JAMA Network Open 7(8):e2426076\u2013e","DOI":"10.1001\/jamanetworkopen.2024.26076"},{"issue":"6","key":"11103_CR162","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391-3","volume":"23","author":"SD Passik","year":"2002","unstructured":"Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E et al (2002) A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 23(6):526\u2013532","journal-title":"J Pain Symptom Manage"},{"key":"11103_CR163","doi-asserted-by":"crossref","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090\u20138","DOI":"10.1002\/cncr.11433"},{"issue":"3","key":"11103_CR164","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27551","volume":"66","author":"V Radhakrishnan","year":"2019","unstructured":"Radhakrishnan V, Joshi A, Ramamoorthy J, Rajaraman S, Ganesan P, Ganesan TS et al (2019) Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer 66(3):e27551","journal-title":"Pediatr Blood Cancer"},{"key":"11103_CR165","volume":"10","author":"V Radhakrishnan","year":"2024","unstructured":"Radhakrishnan V, Venkatakrishnan K, Perumal Kalaiyarasi J, Selvarajan G, Mahaboobasha N, Victor PV et al (2024) Dexamethasone-free antiemetic prophylaxis for highly emetogenic chemotherapy: a double-blind, phase III randomized controlled trial (CINV POD study). JCO Glob Oncol 10:e2300301","journal-title":"JCO Glob Oncol"},{"issue":"3","key":"11103_CR166","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00520-014-2400-3","volume":"23","author":"H Raftopoulos","year":"2015","unstructured":"Raftopoulos H, Cooper W, O\u2019Boyle E, Gabrail N, Boccia R, Gralla RJ (2015) Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 23(3):723\u2013732","journal-title":"Support Care Cancer"},{"issue":"9","key":"11103_CR167","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","volume":"16","author":"BL Rapoport","year":"2015","unstructured":"Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16(9):1079\u20131089","journal-title":"Lancet Oncol"},{"issue":"4","key":"11103_CR168","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"BL Rapoport","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423\u2013431","journal-title":"Support Care Cancer"},{"issue":"7","key":"11103_CR169","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1200\/JCO.1993.11.7.1384","volume":"11","author":"D Razavi","year":"1993","unstructured":"Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L et al (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11(7):1384\u20131390","journal-title":"J Clin Oncol"},{"issue":"3","key":"11103_CR170","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00000421-199106000-00010","volume":"14","author":"F Roila","year":"1991","unstructured":"Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M et al (1991) Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 14(3):238\u201342","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"11103_CR171","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2013.51.4547","volume":"32","author":"F Roila","year":"2014","unstructured":"Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M (2014) Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 32(2):101\u2013106","journal-title":"J Clin Oncol"},{"issue":"4","key":"11103_CR172","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.1991.9.4.675","volume":"9","author":"F Roila","year":"1991","unstructured":"Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M et al (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9(4):675\u2013678","journal-title":"J Clin Oncol"},{"issue":"7","key":"11103_CR173","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-009-0723-2","volume":"18","author":"JA Roscoe","year":"2010","unstructured":"Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudlo BD, Colman L et al (2010) Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 18(7):869\u2013876","journal-title":"Support Care Cancer"},{"issue":"1","key":"11103_CR174","first-page":"113","volume":"51","author":"P Ruff","year":"1994","unstructured":"Ruff P, Paska W, Goedhals L, Pouillart P, Rivi\u00e8re A, Vorobiof D et al (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 51(1):113\u20138","journal-title":"Oncology"},{"issue":"4","key":"11103_CR175","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(15)00615-4","volume":"17","author":"CH Ruhlmann","year":"2016","unstructured":"Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, R\u00f8nnengart E, Halekoh U et al (2016) Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 17(4):509\u2013518","journal-title":"Lancet Oncol"},{"issue":"2","key":"11103_CR176","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115\u2013124","journal-title":"Lancet Oncol"},{"issue":"6","key":"11103_CR177","doi-asserted-by":"crossref","first-page":"e1066","DOI":"10.1002\/onco.13772","volume":"26","author":"C Sakai","year":"2021","unstructured":"Sakai C, Shimokawa M, Iihara H, Fujita Y, Ikemura S, Hirose C et al (2021) Low-dose olanzapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic malignancies: a prospective multicenter phase II trial. Oncologist 26(6):e1066\u2013e1072","journal-title":"Oncologist"},{"issue":"14","key":"11103_CR178","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.22.01997","volume":"41","author":"L Sandhya","year":"2023","unstructured":"Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M et al (2023) Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol 41(14):2617\u20132627","journal-title":"J Clin Oncol"},{"issue":"5","key":"11103_CR179","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/jjco\/hyw011","volume":"46","author":"J Sato","year":"2016","unstructured":"Sato J, Kashiwaba M, Komatsu H, Ishida K, Nihei S, Kudo K (2016) Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy. Jpn J Clin Oncol 46(5):415\u2013420","journal-title":"Jpn J Clin Oncol"},{"issue":"30","key":"11103_CR180","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt T, Goldschmidt H, Neben K, Freiberger A, H\u00fcsing J, Gronkowski M et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32(30):3413\u20133420","journal-title":"J Clin Oncol"},{"issue":"12","key":"11103_CR181","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2217\/fon-2016-0070","volume":"12","author":"ID Schnadig","year":"2016","unstructured":"Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE Jr, Taylor C et al (2016) APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol 12(12):1469\u20131481","journal-title":"Future Oncol"},{"issue":"3","key":"11103_CR182","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1634\/theoncologist.2019-0527","volume":"25","author":"L Schwartzberg","year":"2020","unstructured":"Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K et al (2020) Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. Oncologist 25(3):e589\u2013e597","journal-title":"Oncologist"},{"issue":"7","key":"11103_CR183","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","volume":"29","author":"L Schwartzberg","year":"2018","unstructured":"Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D et al (2018) Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol 29(7):1535\u20131540","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"11103_CR184","doi-asserted-by":"crossref","first-page":"e21700","DOI":"10.1200\/JCO.2016.34.15_suppl.e21700","volume":"34","author":"LS Schwartzberg","year":"2016","unstructured":"Schwartzberg LS, Gabrail NY, Hrom JS, Vogelzang NJ, Mosier M, Geller RB et al (2016) Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender. J Clin Oncol 34(15_suppl):e21700","journal-title":"J Clin Oncol"},{"issue":"9","key":"11103_CR185","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","volume":"16","author":"LS Schwartzberg","year":"2015","unstructured":"Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 16(9):1071\u20131078","journal-title":"Lancet Oncol"},{"issue":"2","key":"11103_CR186","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00520-015-2865-8","volume":"24","author":"YM Seol","year":"2016","unstructured":"Seol YM, Kim HJ, Choi YJ, Lee EM, Kim YS, Oh SY et al (2016) Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer 24(2):945\u2013952","journal-title":"Support Care Cancer"},{"key":"11103_CR187","doi-asserted-by":"crossref","first-page":"S1339","DOI":"10.1016\/j.annonc.2021.08.2144","volume":"32","author":"K Shimomura","year":"2021","unstructured":"Shimomura K, Minatogawa H, Mashiko T, Arioka H, Iihara H, Sugawara M et al (2021) LBA63 placebo-controlled, double-blinded phase & #x2162; study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial. Ann Oncol 32:S1339\u2013S1340","journal-title":"Ann Oncol"},{"issue":"10","key":"11103_CR188","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/1097-0142(19921115)70:10<2524::AID-CNCR2820701022>3.0.CO;2-Z","volume":"70","author":"GW Sledge Jr","year":"1992","unstructured":"Sledge GW Jr, Einhorn L, Nagy C, House K (1992) Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70(10):2524\u20132528","journal-title":"Cancer"},{"issue":"Suppl 1","key":"11103_CR189","first-page":"S15","volume":"26","author":"M Soukop","year":"1990","unstructured":"Soukop M (1990) A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. Eur J Cancer 26(Suppl 1):S15\u20139","journal-title":"Eur J Cancer"},{"issue":"2\u20133","key":"11103_CR190","first-page":"219","volume":"64","author":"N Steele","year":"1980","unstructured":"Steele N, Gralla RJ, Braun DW Jr, Young CW (1980) Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 64(2\u20133):219\u2013224","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"11103_CR191","first-page":"202","volume":"52","author":"A Stewart","year":"1995","unstructured":"Stewart A, McQuade B, Cronje JD, Goedhals L, Gudgeon A, Corette L et al (1995) Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology 52(3):202\u201310","journal-title":"Oncology"},{"issue":"1","key":"11103_CR192","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbmt.2012.07.019","volume":"19","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D et al (2013) Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19(1):49-55.e1","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"11103_CR193","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.1985.3.2.245","volume":"3","author":"SB Strum","year":"1985","unstructured":"Strum SB, McDermed JE, Liponi DF (1985) High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. J Clin Oncol 3(2):245\u2013251","journal-title":"J Clin Oncol"},{"issue":"6","key":"11103_CR194","first-page":"1432","volume":"53","author":"SB Strum","year":"1984","unstructured":"Strum SB, McDermed JE, Pileggi J, Riech LP, Whitaker H (1984) Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation Cancer 53(6):1432\u20131439","journal-title":"A preliminary evaluation Cancer"},{"issue":"22","key":"11103_CR195","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1002\/cncr.32429","volume":"125","author":"S Sugawara","year":"2019","unstructured":"Sugawara S, Inui N, Kanehara M, Morise M, Yoshimori K, Kumagai T et al (2019) Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer 125(22):4076\u20134083","journal-title":"Cancer"},{"issue":"9","key":"11103_CR196","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/jog.13378","volume":"43","author":"Y Sugimori","year":"2017","unstructured":"Sugimori Y, Ota T, Ujihira T, Ishiguro T, Ogishima D (2017) A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer. J Obstet Gynaecol Res 43(9):1454\u20131459","journal-title":"J Obstet Gynaecol Res"},{"issue":"6","key":"11103_CR197","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.31557\/APJCP.2022.23.6.2137","volume":"23","author":"S Sukauichai","year":"2022","unstructured":"Sukauichai S, Ketkaew C, Othaganont N, Pichaya P, Promsuwan P (2022) Efficacy of olanzapine 5 mg versus 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting in patients receiving high emetic risk chemotherapy without neurokinin-1 receptor antagonist. Asian Pac J Cancer Prev 23(6):2137\u20132143","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"11103_CR198","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219\u2013227","journal-title":"Support Care Cancer"},{"issue":"3","key":"11103_CR199","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3904\/kjim.2020.359","volume":"38","author":"S Sun","year":"2023","unstructured":"Sun S, Ko YH, Jin JY, Woo IS, Park SY, Eom YA et al (2023) Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial. Korean J Intern Med 38(3):406\u2013416","journal-title":"Korean J Intern Med"},{"issue":"8","key":"11103_CR200","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R et al (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27(8):1601\u20131606","journal-title":"Ann Oncol"},{"issue":"1","key":"11103_CR201","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","volume":"22","author":"H Takemoto","year":"2017","unstructured":"Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R et al (2017) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol 22(1):88\u201395","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"11103_CR202","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20(5):855\u2013865","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"11103_CR203","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10147-016-1069-7","volume":"22","author":"K Tamura","year":"2017","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H et al (2017) Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol 22(2):405\u2013412","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"11103_CR204","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H et al (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28(1):131","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"11103_CR205","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","volume":"84","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y et al (2019) Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 84(1):147\u2013153","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"11103_CR206","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bjc.2013.400","volume":"109","author":"M Tanioka","year":"2013","unstructured":"Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K et al (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109(4):859\u2013865","journal-title":"Br J Cancer"},{"issue":"4","key":"11103_CR207","doi-asserted-by":"crossref","first-page":"372","DOI":"10.21037\/apm.2019.08.04","volume":"8","author":"P Tienchaiananda","year":"2019","unstructured":"Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-Nguansai S, Payapwattanawong S, Laohavinij S et al (2019) A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Ann Palliat Med 8(4):372\u2013380","journal-title":"Ann Palliat Med"},{"issue":"1","key":"11103_CR208","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1634\/theoncologist.2020-0305","volume":"26","author":"M van der Vorst","year":"2021","unstructured":"van der Vorst M, Toffoli EC, Beusink M, van Linde ME, van Voorthuizen T, Brouwer S et al (2021) Metoclopramide, dexamethasone, or palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy (MEDEA): a randomized, phase III, noninferiority trial. Oncologist 26(1):e173\u2013e181","journal-title":"Oncologist"},{"issue":"7","key":"11103_CR209","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011\u20131015","journal-title":"Br J Cancer"},{"issue":"2","key":"11103_CR210","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s10147-019-01570-3","volume":"25","author":"V Vimolchalao","year":"2020","unstructured":"Vimolchalao V, Sakdejayont S, Wongchanapai P, Sukprakun S, Angspatt P, Thawinwisan W et al (2020) The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Int J Clin Oncol 25(2):396\u2013402","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"11103_CR211","volume":"4","author":"DS Wang","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, Ren C, Qiu MZ, Luo HY et al (2021) Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open 4(4):e215250","journal-title":"JAMA Netw Open"},{"issue":"12","key":"11103_CR212","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822\u20132830","journal-title":"J Clin Oncol"},{"issue":"6","key":"11103_CR213","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","volume":"19","author":"DG Warr","year":"2011","unstructured":"Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 19(6):807\u2013813","journal-title":"Support Care Cancer"},{"issue":"1","key":"11103_CR214","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/annonc\/mdv482","volume":"27","author":"C Weinstein","year":"2016","unstructured":"Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E et al (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27(1):172\u2013178","journal-title":"Ann Oncol"},{"issue":"3","key":"11103_CR215","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"H Yahata","year":"2016","unstructured":"Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T et al (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21(3):491\u2013497","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"11103_CR216","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K et al (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23(2):382\u2013388","journal-title":"Int J Clin Oncol"},{"key":"11103_CR217","doi-asserted-by":"crossref","unstructured":"Yang LQ, Sun XC, Qin SK, Cheng Y, Shi JH, Chen ZD et al (2017) Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: a randomized, double-blind, phase III study. Eur J Cancer Care (Engl) 26(6).\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/28393417\/","DOI":"10.1111\/ecc.12668"},{"issue":"8","key":"11103_CR218","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00277-022-04877-w","volume":"101","author":"P Ye","year":"2022","unstructured":"Ye P, Pei R, Wang T, Cao J, Zhang P, Chen D et al (2022) Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study. Ann Hematol 101(8):1835\u20131841","journal-title":"Ann Hematol"},{"key":"11103_CR219","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","volume":"50","author":"W Yeo","year":"2020","unstructured":"Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M et al (2020) A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast 50:30\u201338","journal-title":"Breast"},{"issue":"2","key":"11103_CR220","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"L Zhang","year":"2018","unstructured":"Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D et al (2018) A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 29(2):452\u2013458","journal-title":"Ann Oncol"},{"issue":"31","key":"11103_CR221","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2017.72.2538","volume":"35","author":"L Zhang","year":"2017","unstructured":"Zhang L, Qu X, Teng Y, Shi J, Yu P, Sun T et al (2017) Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: a randomized, multicenter, double-blind, placebo-controlled phase III trial (CLOG1302 study). J Clin Oncol 35(31):3558\u20133565","journal-title":"J Clin Oncol"},{"key":"11103_CR222","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101771","volume":"55","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Yang Y, Gao F, Hu C, Zhong D, Lu M et al (2023) A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine 55:101771","journal-title":"EClinicalMedicine"},{"issue":"2","key":"11103_CR223","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cac2.12397","volume":"43","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhao B, Chen G, Chen Y, Liao Z, Zhang H et al (2023) Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer Commun (Lond) 43(2):246\u2013256","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"11103_CR224","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41591-025-03926-x","volume":"31","author":"R Casolino","year":"2025","unstructured":"Casolino R, Tatah L, Charnaud S, Santero M, Ilbawi A, Ross AL (2025) The WHO global landscape of cancer clinical trials. Nat Med 31(9):2901\u20132912","journal-title":"Nat Med"},{"issue":"6","key":"11103_CR225","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(23)00182-1","volume":"24","author":"SA McIntosh","year":"2023","unstructured":"McIntosh SA, Alam F, Adams L, Boon IS, Callaghan J, Conti I et al (2023) Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments. Lancet Oncol 24(6):636\u2013645","journal-title":"Lancet Oncol"},{"issue":"3","key":"11103_CR226","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaoncol.2020.7478","volume":"7","author":"JC Wells","year":"2021","unstructured":"Wells JC, Sharma S, Del Paggio JC, Hopman WM, Gyawali B, Mukherji D et al (2021) An analysis of contemporary oncology randomized clinical trials from low\/middle-income vs high-income countries. JAMA Oncol 7(3):379\u2013385","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"11103_CR227","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e24075","volume":"43","author":"M Kapoor","year":"2025","unstructured":"Kapoor M, Sundriyal D, Sehrawat A, Bahurupi YA (2025) Patient-specific factors as predictors of chemotherapy-induced nausea and vomiting: insights from a lower-middle-income setting. J Clin Oncol 43(16_suppl):e24075\u2013e","journal-title":"J Clin Oncol"},{"key":"#cr-split#-11103_CR228.1","unstructured":"Moore C, Bourque MS, Halman A, Ag\u00fandez JAG, Prows CA, Hikino K et al (2026) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of 5-HT"},{"key":"#cr-split#-11103_CR228.2","unstructured":"(3) receptor antagonists: 2026 update. Clin Pharmacol Ther.\u00a0https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70291?af=R"},{"issue":"4","key":"11103_CR229","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/01635581.2018.1527375","volume":"71","author":"S Najafi","year":"2019","unstructured":"Najafi S, Haghighat S, Raji Lahiji M, RazmPoosh E, Chamari M, Abdollahi R et al (2019) Randomized study of the effect of dietary counseling during adjuvant chemotherapy on chemotherapy induced nausea and vomiting, and quality of life in patients with breast cancer. Nutr Cancer 71(4):575\u2013584","journal-title":"Nutr Cancer"},{"issue":"8","key":"11103_CR230","doi-asserted-by":"crossref","first-page":"879","DOI":"10.6004\/jnccn.2022.7029","volume":"20","author":"BE Wilson","year":"2022","unstructured":"Wilson BE, Pearson SA, Barton MB, Amir E (2022) Regional variations in clinical trial outcomes in oncology. J Natl Compr Canc Netw 20(8):879\u201386.e2","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11103-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:05:14Z","timestamp":1790366714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11103-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":231,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["11103"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11103-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"857"}}